140 related articles for article (PubMed ID: 24138940)
1. Structure-based design and synthesis of potent benzothiazole inhibitors of interleukin-2 inducible T cell kinase (ITK).
MacKinnon CH; Lau K; Burch JD; Chen Y; Dines J; Ding X; Eigenbrot C; Heifetz A; Jaochico A; Johnson A; Kraemer J; Kruger S; Krülle TM; Liimatta M; Ly J; Maghames R; Montalbetti CA; Ortwine DF; Pérez-Fuertes Y; Shia S; Stein DB; Trani G; Vaidya DG; Wang X; Bromidge SM; Wu LC; Pei Z
Bioorg Med Chem Lett; 2013 Dec; 23(23):6331-5. PubMed ID: 24138940
[TBL] [Abstract][Full Text] [Related]
2. Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
Pastor RM; Burch JD; Magnuson S; Ortwine DF; Chen Y; De La Torre K; Ding X; Eigenbrot C; Johnson A; Liimatta M; Liu Y; Shia S; Wang X; Wu LC; Pei Z
Bioorg Med Chem Lett; 2014 Jun; 24(11):2448-52. PubMed ID: 24767842
[TBL] [Abstract][Full Text] [Related]
3. Discovery, SAR and X-ray structure of 1H-benzimidazole-5-carboxylic acid cyclohexyl-methyl-amides as inhibitors of inducible T-cell kinase (Itk).
Moriarty KJ; Takahashi H; Pullen SS; Khine HH; Sallati RH; Raymond EL; Woska JR; Jeanfavre DD; Roth GP; Winters MP; Qiao L; Ryan D; DesJarlais R; Robinson D; Wilson M; Bobko M; Cook BN; Lo HY; Nemoto PA; Kashem MA; Wolak JP; White A; Magolda RL; Tomczuk B
Bioorg Med Chem Lett; 2008 Oct; 18(20):5545-9. PubMed ID: 18819799
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug design.
Cook BN; Bentzien J; White A; Nemoto PA; Wang J; Man CC; Soleymanzadeh F; Khine HH; Kashem MA; Kugler SZ; Wolak JP; Roth GP; De Lombaert S; Pullen SS; Takahashi H
Bioorg Med Chem Lett; 2009 Feb; 19(3):773-7. PubMed ID: 19111460
[TBL] [Abstract][Full Text] [Related]
5. Fragment Molecular Orbital Method Applied to Lead Optimization of Novel Interleukin-2 Inducible T-Cell Kinase (ITK) Inhibitors.
Heifetz A; Trani G; Aldeghi M; MacKinnon CH; McEwan PA; Brookfield FA; Chudyk EI; Bodkin M; Pei Z; Burch JD; Ortwine DF
J Med Chem; 2016 May; 59(9):4352-63. PubMed ID: 26950250
[TBL] [Abstract][Full Text] [Related]
6. Property- and structure-guided discovery of a tetrahydroindazole series of interleukin-2 inducible T-cell kinase inhibitors.
Burch JD; Lau K; Barker JJ; Brookfield F; Chen Y; Chen Y; Eigenbrot C; Ellebrandt C; Ismaili MH; Johnson A; Kordt D; MacKinnon CH; McEwan PA; Ortwine DF; Stein DB; Wang X; Winkler D; Yuen PW; Zhang Y; Zarrin AA; Pei Z
J Med Chem; 2014 Jul; 57(13):5714-27. PubMed ID: 24918870
[TBL] [Abstract][Full Text] [Related]
7. Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.
Charrier JD; Miller A; Kay DP; Brenchley G; Twin HC; Collier PN; Ramaya S; Keily SB; Durrant SJ; Knegtel RM; Tanner AJ; Brown K; Curnock AP; Jimenez JM
J Med Chem; 2011 Apr; 54(7):2341-50. PubMed ID: 21391610
[TBL] [Abstract][Full Text] [Related]
8. Optimisation of ITK inhibitors through successive iterative design cycles.
Herdemann M; Weber A; Jonveaux J; Schwoebel F; Stoeck M; Heit I
Bioorg Med Chem Lett; 2011 Mar; 21(6):1852-6. PubMed ID: 21316219
[TBL] [Abstract][Full Text] [Related]
9. Identification of potent ITK inhibitors through focused compound library design including structural information.
Herdemann M; Heit I; Bosch FU; Quintini G; Scheipers C; Weber A
Bioorg Med Chem Lett; 2010 Dec; 20(23):6998-7003. PubMed ID: 20965724
[TBL] [Abstract][Full Text] [Related]
10. Covalent inhibitors of interleukin-2 inducible T cell kinase (itk) with nanomolar potency in a whole-blood assay.
Zapf CW; Gerstenberger BS; Xing L; Limburg DC; Anderson DR; Caspers N; Han S; Aulabaugh A; Kurumbail R; Shakya S; Li X; Spaulding V; Czerwinski RM; Seth N; Medley QG
J Med Chem; 2012 Nov; 55(22):10047-63. PubMed ID: 23098091
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and structure-activity relationships of a novel class of sulfonylpyridine inhibitors of Interleukin-2 inducible T-cell kinase (ITK).
Trani G; Barker JJ; Bromidge SM; Brookfield FA; Burch JD; Chen Y; Eigenbrot C; Heifetz A; Ismaili MHA; Johnson A; Krülle TM; MacKinnon CH; Maghames R; McEwan PA; Montalbetti CAGN; Ortwine DF; Pérez-Fuertes Y; Vaidya DG; Wang X; Zarrin AA; Pei Z
Bioorg Med Chem Lett; 2014 Dec; 24(24):5818-5823. PubMed ID: 25455497
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of novel (4 or 5-aryl)pyrazolyl-indoles as inhibitors of interleukin-2 inducible T-cell kinase (ITK).
Velankar AD; Quintini G; Prabhu A; Weber A; Hunaeus G; Voland B; Wuest M; Orjeda C; Harel D; Varghese S; Gore V; Patil M; Gayke D; Herdemann M; Heit I; Zaliani A
Bioorg Med Chem; 2010 Jun; 18(12):4547-59. PubMed ID: 20472447
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and structure-activity relationship of indolylindazoles as potent and selective covalent inhibitors of interleukin-2 inducible T-cell kinase (ITK).
Wang X; Xue G; Pan Z
Eur J Med Chem; 2020 Feb; 187():111918. PubMed ID: 31830635
[TBL] [Abstract][Full Text] [Related]
14. 5-Aminomethyl-1H-benzimidazoles as orally active inhibitors of inducible T-cell kinase (Itk).
Winters MP; Robinson DJ; Khine HH; Pullen SS; Woska JR; Raymond EL; Sellati R; Cywin CL; Snow RJ; Kashem MA; Wolak JP; King J; Kaplita PV; Liu LH; Farrell TM; DesJarlais R; Roth GP; Takahashi H; Moriarty KJ
Bioorg Med Chem Lett; 2008 Oct; 18(20):5541-4. PubMed ID: 18823779
[TBL] [Abstract][Full Text] [Related]
15. Benzothiazoles as Rho-associated kinase (ROCK-II) inhibitors.
Yin Y; Lin L; Ruiz C; Cameron MD; Pocas J; Grant W; Schröter T; Chen W; Duckett D; Schürer S; Lograsso P; Feng Y
Bioorg Med Chem Lett; 2009 Dec; 19(23):6686-90. PubMed ID: 19837589
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors.
Wang X; Sarris K; Kage K; Zhang D; Brown SP; Kolasa T; Surowy C; El Kouhen OF; Muchmore SW; Brioni JD; Stewart AO
J Med Chem; 2009 Jan; 52(1):170-80. PubMed ID: 19072118
[TBL] [Abstract][Full Text] [Related]
17. Itk kinase inhibitors: initial efforts to improve the metabolical stability and the cell activity of the benzimidazole lead.
Moriarty KJ; Winters M; Qiao L; Ryan D; DesJarlis R; Robinson D; Cook BN; Kashem MA; Kaplita PV; Liu LH; Farrell TM; Khine HH; King J; Pullen SS; Roth GP; Magolda R; Takahashi H
Bioorg Med Chem Lett; 2008 Oct; 18(20):5537-40. PubMed ID: 18819794
[TBL] [Abstract][Full Text] [Related]
18. Selectively targeting an inactive conformation of interleukin-2-inducible T-cell kinase by allosteric inhibitors.
Han S; Czerwinski RM; Caspers NL; Limburg DC; Ding W; Wang H; Ohren JF; Rajamohan F; McLellan TJ; Unwalla R; Choi C; Parikh MD; Seth N; Edmonds J; Phillips C; Shakya S; Li X; Spaulding V; Hughes S; Cook A; Robinson C; Mathias JP; Navratilova I; Medley QG; Anderson DR; Kurumbail RG; Aulabaugh A
Biochem J; 2014 Jun; 460(2):211-22. PubMed ID: 24593284
[TBL] [Abstract][Full Text] [Related]
19. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors.
D'Angelo ND; Kim TS; Andrews K; Booker SK; Caenepeel S; Chen K; D'Amico D; Freeman D; Jiang J; Liu L; McCarter JD; San Miguel T; Mullady EL; Schrag M; Subramanian R; Tang J; Wahl RC; Wang L; Whittington DA; Wu T; Xi N; Xu Y; Yakowec P; Yang K; Zalameda LP; Zhang N; Hughes P; Norman MH
J Med Chem; 2011 Mar; 54(6):1789-811. PubMed ID: 21332118
[TBL] [Abstract][Full Text] [Related]
20. X-ray crystallographic structure-based design of selective thienopyrazole inhibitors for interleukin-2-inducible tyrosine kinase.
McLean LR; Zhang Y; Zaidi N; Bi X; Wang R; Dharanipragada R; Jurcak JG; Gillespy TA; Zhao Z; Musick KY; Choi YM; Barrague M; Peppard J; Smicker M; Duguid M; Parkar A; Fordham J; Kominos D
Bioorg Med Chem Lett; 2012 May; 22(9):3296-300. PubMed ID: 22464456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
